EUVIMEDOpdag EUVIMED
Crossref

Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up

Candy Cahilog, Romina Danguilan, Paolo Miguel David, Mel-Hatra Arakama, Glenda Eleanor Pamugas

Korean Journal of Transplantation · 2020

DOI: 10.4285/atw2020.op-1026 ↗

At a glance

Journal article in Korean Journal of Transplantation, 2020. Written by Candy Cahilog and 4 co-authors.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Kidney transplantation has significantly improved survival and quality of life of patients with end-stage renal disease and is considered the best form of renal replacement therapy. Rabbit anti-thymocyte globulin (rATG) has commonly been reserved for high immunologic risk patients and the resulting profound depression in immune response is associated with an increased risk for infection.

Methods

A retrospective cohort of patients transplanted from June 2012 to December 2014 was done to evaluate the short-and long-term outcome and efficacy of low dose rATG versus basiliximab as induction. CNI-based triple immunosuppression was given to the majority of patients.

Results

Among 165 patients in the study, 131 were given basiliximab and 34 were given low dose rATG (1-1.5 mg/kg/day for 3 days). The two groups were similar in mean age, native kidney disease, and cytomegalovirus (CMV) status. Higher proportion of patients who received rATG had positive panel reactive antibody (P=0.0003), higher human leucocyte antigen mismatches (P=0.0023), and non-related donors (P=0.025). Low dose rATG and basiliximab as induction therapy resulted in comparable outcomes including DGF, graft function, proteinuria, incidence of acute rejection and post-transplant malignancy. Incidence of infection was significantly higher in basiliximab group at 3-year post-KT: 11.5% vs. 0, P=0.04. CMV infection occurred very low at an overall rate of 0.6% at 1-and 3-year post-KT. Graft and patient survival at 5-year post-KT were 96.9% vs. 97.1%, P=0.99 and 99% vs. 100%, P=0.57, respectively.

Conclusions

Both low dose rATG and basiliximab induction resulted in excellent long-term outcomes. Low dose rATG was not associated with higher infection rates and can be used safely in standard risk patients.

Cite

APA

Cahilog, C., Danguilan, R., David, P. M., Arakama, M., & Pamugas, G. E. (2020). Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. https://doi.org/10.4285/atw2020.op-1026

Vancouver

Cahilog C, Danguilan R, David PM, Arakama M, Pamugas GE. Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. 2020. doi:10.4285/atw2020.op-1026

BibTeX
@article{Cahilog2020,
  author = {Cahilog, Candy and Danguilan, Romina and David, Paolo Miguel and Arakama, Mel-Hatra and Pamugas, Glenda Eleanor},
  title = {Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up},
  journal = {Korean Journal of Transplantation},
  year = {2020},
  doi = {10.4285/atw2020.op-1026}
}
Start for free →